Galecto, Inc.

DMRASEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1800315

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$23.8M	$48.2M	$38.5M	$24.6M	$19.7M
Operating Expenses	$39.9M	$61.2M	$52.2M	$33.6M	$39.0M
Operating Income (Loss)	-$39.9M	-$61.2M	-$52.2M	-$33.6M	$39.0M
Nonoperating Income (Expense)	$1.6M	-$417.0K	$475.0K	-$1.2M	$2.5M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$38.3M	-$61.6M	-$51.8M	-$34.8M	-$36.5M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$38.3M	-$61.6M	-$51.8M	-$34.8M	-$36.5M
Earnings Per Share, Basic	-$36.08	-$2.43	-$2.05	—	—
Earnings Per Share, Diluted	-$36.08	-$2.43	-$2.05	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$38.2M	$73.2M	$122.2M	$171.6M	$56.6M
Assets, Current	$36.8M	$63.9M	$110.1M	$169.3M	$56.1M
Cash and Cash Equivalents, at Carrying Value	$21.5M	$32.8M	$62.6M	$163.6M	$11.3M
Liabilities	$5.9M	$11.4M	$5.0M	$6.1M	$8.1M
Liabilities, Current	$5.8M	$11.1M	$4.5M	$5.6M	$7.9M
Accounts Payable, Current	$1.7M	$3.4M	$1.5M	$2.9M	$3.3M
Stockholders' Equity Attributable to Parent	$61.8M	$117.2M	$165.5M	-$71.1M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$36.9M	-$42.9M	-$52.3M	-$38.2M	-$19.3M
Net Cash Provided by (Used in) Investing Activities	$22.3M	$12.4M	-$48.0M	-$48.0M	-$326.0K
Net Cash Provided by (Used in) Financing Activities	$2.9M	$507.0K	$507.0K	$187.4M	$187.4M
Payments to Acquire Property, Plant, and Equipment	—	$196.0K	$223.0K	$223.0K	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)